Manager

XORTX Welcomes New Member to the Board of Directors

Retrieved on: 
Monday, April 8, 2024
Abbey, Manager, Biotechnology, Pfizer, Business, Emergent, Patient, Vaccine, Research, Senior, Psychology, Kidney disease, Biology, Johns Hopkins University, Therapy, Industry Dive, Pharmaceutical industry

Abigail “Abbey” L. Jenkins, M.S., is the current President and CEO of Gamida Cell (NASDAQ: GMDA) and a member of its Board of Directors.

Key Points: 
  • Abigail “Abbey” L. Jenkins, M.S., is the current President and CEO of Gamida Cell (NASDAQ: GMDA) and a member of its Board of Directors.
  • Ms. Jenkins brings over 20 years of leadership experience in the biopharmaceutical industry delivering life-enhancing therapies from research to commercialization for patients in need.
  • Anthony Giovinazzo, XORTX’s Chairman of the Board commented, “We are delighted to welcome Abbey to the Board of Directors.
  • Abbey is a highly skilled and experienced leader who will significantly contribute to the Board of Directors carrying out its mandate.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Community Health, Inc. - CYH

Retrieved on: 
Sunday, March 31, 2024
CYH, Community, Manager, Community health, News, LLP, DOJ, Annual report, Dialysis, Pomerantz

NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Community Health, Inc. (“Community Health” or the “Company”) (NYSE: CYH).

Key Points: 
  • NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Community Health, Inc. (“Community Health” or the “Company”) (NYSE: CYH).
  • The investigation concerns whether Community Health and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Men, Health, Consumer, Other Health, Pharmaceutical, Surgery, Other Science, Research, Medical Devices, Science, Women, Seniors, Clinical Trials, Week, Sciatica, LDH, Incidence, Ferring Pharmaceuticals, Patient, Spinal disc herniation, Șaeș, University, ESI, Quality of life, Manager, University of Illinois Urbana-Champaign, Society, Back pain, LSM, Pain, SAE

"Based on these findings, SI-6603 could provide another option where a single injection to the lumbar disc could offer patients significant relief from the unrelenting pain often associated with lumbar disc herniation."

Key Points: 
  • "Based on these findings, SI-6603 could provide another option where a single injection to the lumbar disc could offer patients significant relief from the unrelenting pain often associated with lumbar disc herniation."
  • An analysis assessing current treatment patterns and gaps in clinical management of patients with newly diagnosed LDH was also presented.
  • The analysis reviewed medical claims data of more than a million U.S. patients over a four-year period.
  • Among patients who received more than one ESI, one in five (22.4%) underwent surgery with 14.2% of those patients receiving repeated surgeries.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Community Health, Inc. - CYH

Retrieved on: 
Saturday, March 23, 2024
Community, Prior, Manager, Community health, News, LLP, DOJ, Annual report, Dialysis, Pomerantz

NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Community Health, Inc. (“Community Health” or the “Company”) (NYSE: CYH).

Key Points: 
  • NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Community Health, Inc. (“Community Health” or the “Company”) (NYSE: CYH).
  • The investigation concerns whether Community Health and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Community Health, Inc. - CYH

Retrieved on: 
Friday, March 15, 2024
CYH, Community, Manager, Community health, News, LLP, DOJ, Annual report, Dialysis, Pomerantz

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Community Health, Inc. (“Community Health” or the “Company”) (NYSE: CYH).

Key Points: 
  • NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Community Health, Inc. (“Community Health” or the “Company”) (NYSE: CYH).
  • The investigation concerns whether Community Health and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

Luna Innovations Announces CEO Transition

Retrieved on: 
Monday, March 25, 2024
Nanotechnology, Other Technology, Technology, Telecommunications, Software, Manager, Interim, Lead, Safety, Management

Luna Innovations Incorporated (NASDAQ: LUNA) (the “Company”), a global leader in advanced fiber optic-based technology, today announced that Scott Graeff has retired from his role as President and Chief Executive Officer of the Company and has stepped down from the Board of Directors (the “Board”), leaving the Company after 21 years, including the last seven as President and Chief Executive Officer.

Key Points: 
  • Luna Innovations Incorporated (NASDAQ: LUNA) (the “Company”), a global leader in advanced fiber optic-based technology, today announced that Scott Graeff has retired from his role as President and Chief Executive Officer of the Company and has stepped down from the Board of Directors (the “Board”), leaving the Company after 21 years, including the last seven as President and Chief Executive Officer.
  • The Board has initiated a search for a new President and Chief Executive Officer with the support of a leading international search firm.
  • The Board has also established an Operations Committee, comprised of David Chanley, Barry Phelps and Gary Spiegel, to provide focused oversight of the Company during this transition period.
  • “Luna Innovations has a rich history of working in close collaboration with its customers and partners to develop best-in-class sensing, test and measurement, monitoring, and control solutions,” said Mr. Roedel.

Ncontracts Names Brian Lapidus Chief Revenue Officer

Retrieved on: 
Thursday, March 21, 2024
Software, Banking, Mobile, Wireless, Internet, Professional Services, Data Management, Technology, Small Business, Other Professional Services, Finance, Other Technology, Consulting, Vanderbilt University, Manager, Culture, Knowledge as a service, Risk management, Growth, EVP, Environment, Risk, Business administration, Blockchain, Knowledge, Ellipse, Psychology, Workplace, Tennessean, GRC, Workforce, Management

Ncontracts , the leading provider of integrated compliance, risk, and vendor management solutions to the financial services industry, today announced that Brian Lapidus has joined the company as its Chief Revenue Officer (CRO).

Key Points: 
  • Ncontracts , the leading provider of integrated compliance, risk, and vendor management solutions to the financial services industry, today announced that Brian Lapidus has joined the company as its Chief Revenue Officer (CRO).
  • Lapidus will lead Ncontracts’ sales team, spearheading initiatives to accelerate the company’s continued growth.
  • “I’m excited to join Ncontracts and lead a team dedicated to helping financial services companies navigate a highly complex compliance and risk management environment,” said Lapidus.
  • "We are thrilled to welcome Brian to our executive team," said Ncontracts CEO and founder Michael Berman.

Community Health Systems, Inc. (CYH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Retrieved on: 
Thursday, March 14, 2024
Class Action Lawsuit, Professional Services, Legal, CYH, Community, Community Health Systems, Manager, Community health, News, DOJ, Annual report, Dialysis

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Community Health Systems, Inc. (“Community Health” or “the Company”) (NYSE: CYH).

Key Points: 
  • Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Community Health Systems, Inc. (“Community Health” or “the Company”) (NYSE: CYH).
  • Investors who purchased Community Health securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/CYH .
  • On February 21, 2024, Community Health disclosed in its Annual Report for 2023 that it was under investigation by the U.S. Department of Justice (“DOJ”).
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

REGENATIVE LABS' LATEST PUBLISHED STUDY DEMONSTRATES THE SAFETY AND EFFICACY OF WHARTON'S JELLY CONNECTIVE TISSUE ALLOGRAFT FOR ROTATOR CUFF TEARS

Retrieved on: 
Thursday, April 4, 2024
Knee, MDPI, Stiffness, Shoulder, Safety, Hip, Wharton's jelly, Rotator cuff, Patient, Research, Rehabilitation, Quality of life, Manager, Efficacy, WOMAC, Regenerative medicine, Quality, Literature, Spine, Orthopedic surgery, Pain, Calendar, Physician, Injury, WJ, Medicine, Dentistry

PENSACOLA, Fla., April 4, 2024 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces the publication of a study exhibiting the safety and efficacy of Wharton's Jelly connective tissue allograft for rotator cuff tears.

Key Points: 
  • PENSACOLA, Fla., April 4, 2024 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces the publication of a study exhibiting the safety and efficacy of Wharton's Jelly connective tissue allograft for rotator cuff tears.
  • Patients in need of rotator cuff repairs often seek minimally invasive options, making Wharton's Jelly a promising alternative for musculoskeletal defects.
  • Utilizing the structural connective tissue allografts has allowed many patients to avoid surgery altogether and significantly improve their quality of life."
  • The study titled "Safety and Efficacy of Wharton's Jelly Connective Tissue Allograft for Rotator Cuff Tears," was published by MDPI and can be accessed in its entirety here.

Announcing ABQAURP's 2024 Annual Conference - Early Registration Discount Deadline Extended

Retrieved on: 
Wednesday, March 27, 2024
Tax, Conference, Accreditation Council, Communication, Manager, Patient, Knowledge, Artificial intelligence, The Walt Disney Company, Quality assurance, Physician, Nursing, Health, Accreditation, Human

NEW PORT RICHEY, Fla., March 27, 2024 /PRNewswire-PRWeb/ -- ABQAURP's 47th Annual Conference is being presented on September 12-13, 2024, at Disney's BoardWalk Inn in Lake Buena Vista, FL. The annual conference will provide insight into emerging technology, aligning digital quality to care delivery, and strategies to improve processes and utilization while decreasing payment denials. Discover how new strategies can be incorporated without losing sight of the return on investment or quality of care. A panel discussion will examine how the interprofessional health care team can work together to improve care transitions into the community and is committed to advocating for patients and providers as we traverse into the future.

Key Points: 
  • The early registration deadline is extended to attend this event.
  • NEW PORT RICHEY, Fla., March 27, 2024 /PRNewswire-PRWeb/ -- ABQAURP's 47th Annual Conference is being presented on September 12-13, 2024, at Disney's BoardWalk Inn in Lake Buena Vista, FL.
  • The annual conference will provide insight into emerging technology, aligning digital quality to care delivery, and strategies to improve processes and utilization while decreasing payment denials.
  • Discover how new strategies can be incorporated without losing sight of the return on investment or quality of care.